Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2

Objective.To report the efficacy and safety of tocilizumab (TCZ) for giant cell arteritis (GCA).Methods.A retrospective multicenter study that included 34 patients receiving TCZ for GCA.Results.TCZ was effective in all but 6 patients, who still had mild symptoms. Mean glucocorticoid dose was tapered. One patient died and 3 patients had to stop TCZ therapy because of severe adverse events. Twenty-three patients stopped treatment; 8 of these experienced relapses after a mean of 3.5 ± 1.3 months.Conclusion.TCZ is effective in GCA. However, side effects occur. Whether this treatment has only a suspensive effect remains to be determined.

Download Full-text

Cisplatin and Dacarbazine With or Without Subcutaneous Interleukin-2 and Interferon Alfa-2b in Advanced Melanoma Outpatients

Journal of Clinical Oncology ◽

10.1200/jco.2002.99.202 ◽

2002 ◽

Vol 20 (16) ◽

pp. 3560-3561 ◽

Cited By ~ 1

Author(s):

Jhansi Koduri ◽

Michael A. Baumann ◽

Ruggero Ridolfi ◽

Oriana Nanni

Keyword(s):

Interleukin 2 ◽

Advanced Melanoma ◽

Interferon Alfa

Download Full-text

A systematic review of tools for predicting severe adverse events following patient discharge from intensive care units

Critical Care ◽

10.1186/cc12747 ◽

2013 ◽

Vol 17 (3) ◽

pp. R102 ◽

Cited By ~ 42

Author(s):

F Hosein ◽

Niklas Bobrovitz ◽

Simon Berthelot ◽

David Zygun ◽

William A Ghali ◽

...

Keyword(s):

Systematic Review ◽

Intensive Care ◽

Adverse Events ◽

Intensive Care Units ◽

Patient Discharge ◽

Severe Adverse Events

Download Full-text

Antiphospholipid Antibody Induced by Nivolumab

Case Reports in Hematology ◽

10.1155/2018/3106852 ◽

2018 ◽

Vol 2018 ◽

pp. 1-3 ◽

Cited By ~ 2

Author(s):

Ahmed Aburahma ◽

Nour Aljariri Alhesan ◽

Farah Elounais ◽

Emad Abu Sitta

Keyword(s):

Monoclonal Antibody ◽

Adverse Events ◽

Interleukin 2 ◽

Advanced Melanoma ◽

Antiphospholipid Antibody ◽

Gi Tract ◽

The Third ◽

Programmed Death ◽

Prolonged Aptt ◽

Programmed Death Protein 1

Nivolumab is a monoclonal antibody against the programmed death protein 1 and is used for patients with advanced melanoma. It is associated with potentially immune-related adverse events, including disorders of the skin, GI tract, and the thyroid; these disorders were successfully treated with prednisone and infliximab. Other immunotherapeutic agents were observed to induce the formation of antiphospholipid antibody (APA) including α-interferon and interleukin-2. We present a case of APA development after the third dose of nivolumab in a 71-year-old male with advanced melanoma. The APA was detected after finding a prolonged aPTT; the lupus anticoagulant assay tested positive. The patient was treated with prednisone but, unfortunately, he expired a few days later.

Download Full-text

PCN176 USE OF IMMUNE CHECKPOINT INHIBITORS AND RISK OF IMMUNE-RELATED ADVERSE EVENTS AMONG PATIENTS WITH ADVANCED MELANOMA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

Value in Health ◽

10.1016/j.jval.2019.04.298 ◽

2019 ◽

Vol 22 ◽

pp. S89

Author(s):

C.Y. Chang ◽

H. Park ◽

W. Lo-Ciganic

Keyword(s):

Systematic Review ◽

Adverse Events ◽

Immune Checkpoint ◽

Immune Checkpoint Inhibitors ◽

Checkpoint Inhibitors ◽

Meta Analysis ◽

Advanced Melanoma

Download Full-text

A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues

Vaccines ◽

10.3390/vaccines9121387 ◽

2021 ◽

Vol 9 (12) ◽

pp. 1387

Author(s):

Shahad Saif Khandker ◽

Brian Godman ◽

Md. Irfan Jawad ◽

Bushra Ayat Meghla ◽

Taslima Akter Tisha ◽

...

Keyword(s):

Systematic Review ◽

Side Effects ◽

Adverse Events ◽

Drug Administration ◽

Food And Drug Administration ◽

Morbidity And Mortality ◽

European Medicines Agency ◽

Vaccine Candidates ◽

Online Databases ◽

The Us

COVID-19 vaccines are indispensable, with the number of cases and mortality still rising, and currently no medicines are routinely available for reducing morbidity and mortality, apart from dexamethasone, although others are being trialed and launched. To date, only a limited number of vaccines have been given emergency use authorization by the US Food and Drug Administration and the European Medicines Agency. There is a need to systematically review the existing vaccine candidates and investigate their safety, efficacy, immunogenicity, unwanted events, and limitations. The review was undertaken by searching online databases, i.e., Google Scholar, PubMed, and ScienceDirect, with finally 59 studies selected. Our findings showed several types of vaccine candidates with different strategies against SARS-CoV-2, including inactivated, mRNA-based, recombinant, and nanoparticle-based vaccines, are being developed and launched. We have compared these vaccines in terms of their efficacy, side effects, and seroconversion based on data reported in the literature. We found mRNA vaccines appeared to have better efficacy, and inactivated ones had fewer side effects and similar seroconversion in all types of vaccines. Overall, global variant surveillance and systematic tweaking of vaccines, coupled with the evaluation and administering vaccines with the same or different technology in successive doses along with homologous and heterologous prime-booster strategy, have become essential to impede the pandemic. Their effectiveness appreciably outweighs any concerns with any adverse events.

Download Full-text

Efficacy and Safety of Tripterygium Glycoside in the Treatment of Diabetic Nephropathy: A Systematic Review and Meta-Analysis Based on the Duration of Medication

Frontiers in Endocrinology ◽

10.3389/fendo.2021.656621 ◽

2021 ◽

Vol 12 ◽

Author(s):

Yizhen Li ◽

Runpei Miao ◽

Yixing Liu ◽

Jiawei Zhang ◽

Zhili Dou ◽

...

Keyword(s):

Systematic Review ◽

Clinical Trial ◽

Diabetic Nephropathy ◽

Adverse Events ◽

Treatment Duration ◽

Meta Analysis ◽

Efficacy And Safety ◽

Severe Adverse Events ◽

Blood Creatinine

AimThe aim of this study was to assess the clinical efficacy and safety of Tripterygium-derived glycosides (TG) after 3-month and 6-month of treatments of diabetic nephropathy (DN) and to resolve the conflict between medicine guidance and clinical practice for TG application.MethodsWe conducted a systematic review and meta-analysis of randomized controlled trials involving TG application in treating DN. We extensively searched PubMed, Cochrane Library, CNKI, VIP, Wan-Fang, CBM, Chinese Clinical Trial Registry, and WHO International Clinical Trial Registration Platform till November 2020, along with grey literature for diabetes and all other relevant publications to gather eligible studies. Based on the preset inclusion and exclusion criteria, document screening, quality assessment of methodology, and data extraction was conducted by two researchers independently. The methodological quality was assessed by the Cochrane risk test from the Cochrane Handbook 5.2, and then analyses were performed by Review Manager 5.3 (Rev Man 5.3). The quality of output evidence was classified by GRADE.ResultsThirty-one eligible studies (2764 patients) were included for this meta-analysis. Our study results showed a comparable significant decrease in the 24 h-UTP and blood creatinine levels in DN patients from both 3-month and 6-month TG treatment groups, compared with the routine symptomatic treatment alone. To the contrary of the findings from the included studies, our results showed that the occurrence of serious adverse reaction events was significantly higher in the TG treated group with 6 months of treatment duration compared to that of 3 months of the treatment course. However, the total AR ratio was slightly varied while increasing the percent of severe adverse events. GRADE assessment indicated that the quality of evidence investigating TG-induced adverse reactions was moderate and that for 24 h-UTP and blood creatinine indicators were considerably low.ConclusionCombinatorial treatment regimen including TG can significantly decrease the pathological indicators for DN progression, while it can also simultaneously predispose the patient to a higher risk for developing severe adverse events, as the medicine guidance indicates. Notably, even in 3-month of course duration smaller percent of severe adverse events can get to a fatal high percent and is likely to increase proportionally as the TG treatment continues. This suggests that TG-mediated DN treatment duration should be optimized to even less than 3 continuous months to avoid adverse event onset-associated further medical complications in DN patients. In clinical practice, serious attention should be paid to these severe side-effects even in a course normally considered safe, and importantly more high-quality studies are urgently warranted to obtain detailed insights into the balance between the efficacy and safety profiles of TG application in treating DN.

Download Full-text